Free tool
FAERS Monitor: Takhzyro
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming BLA 761090 or its brand name (Takhzyro, Lanadelumab-Flyo). Reports on generic versions are filed under their own applications.
Reports
3,228
Serious
1,536
48% of reports
Hospitalization
870
Death reported
41
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- hereditary angioedema1,217
- drug ineffective298
- product dose omission issue265
- weight increased245
- weight decreased238
- headache188
- condition aggravated187
- inappropriate schedule of product administration169
- product use issue161
- intentional product use issue157
- injection site pain143
- stress143
- malaise128
- pharyngeal swelling123
- off label use122
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2015 | 4 |
| 2016 | 2 |
| 2017 | 5 |
| 2018 | 106 |
| 2019 | 393 |
| 2020 | 318 |
| 2021 | 291 |
| 2022 | 325 |
| 2023 | 374 |
| 2024 | 474 |
| 2025 | 563 |
| 2026 | 373 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,050,931 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| hereditary angioedemaSignal | 1,217 | 833.2 | 793.6 | 896,716 |
| pharyngeal swellingSignal | 123 | 82.9 | 69.7 | 9,756 |
| stressSignal | 143 | 12.9 | 11.0 | 1,567 |
| intentional product use issueSignal | 157 | 11.7 | 10.0 | 1,529 |
| weight increasedSignal | 245 | 7.1 | 6.3 | 1,299 |
| inappropriate schedule of product administrationSignal | 169 | 6.1 | 5.3 | 723 |
| product dose omission issueSignal | 265 | 5.9 | 5.2 | 1,082 |
| product use issueSignal | 161 | 5.6 | 4.8 | 606 |
| weight decreasedSignal | 238 | 5.6 | 4.9 | 896 |
| condition aggravatedSignal | 187 | 4.0 | 3.5 | 425 |
| injection site painSignal | 143 | 3.0 | 2.6 | 196 |
| headache | 188 | 2.0 | 1.7 | 89 |
| malaise | 128 | 1.9 | 1.6 | 55 |
| drug ineffective | 298 | 1.5 | 1.3 | 48 |
| off label use | 122 | 0.9 | 0.8 | 1 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.